Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection.

Abstract

PURPOSE:

To report a case of anterior uveitis and ocular hypotony during HPMPC treatment of a cytomegalovirus infection without ophthalmic involvement.

METHODS:

A 61-year-old bisexual white man with AIDS presented with moderate anterior uveitis and ocular hypotony after 8 weeks of intravenous HPMPC and oral probenecid co-treatment of a presumed recurrence of cytomegalovirus encephalitis.

RESULTS:

There was no evidence of an ocular cytomegalovirus infection. Cidofovir-related uveitis was diagnosed, and the HPMPC-probenecid co-treatment was switched to ganciclovir monotherapy. The ocular inflammation was successfully managed with topical steroids and mydriatics.

CONCLUSIONS:

This description of ophthalmic side effects from systemic HPMPC in the absence of ocular cytomegalovirus infection supports the hypothesis that anterior uveitis and ocular hypotony result from a direct interaction between the drug and the ciliary body.

• Authors: R A Scott, C Pavesio
• Journal: American journal of ophthalmology (Am J Ophthalmol) Vol. 130 Issue 1 Pg. 126-7 (Jul 2000) ISSN: 0002-9394 [Print] United States
• PMID: 11004276 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antiviral Agents
• Organophosphonates
• Organophosphorus Compounds
• Cytosine
• Cidofovir
• Probenecid

Topics

• AIDS-Related Opportunistic Infections (drug therapy)
• Antiviral Agents (adverse effects, therapeutic use)
• Cidofovir
• Cytomegalovirus Infections (drug therapy)
• Cytosine (adverse effects, analogs & derivatives, therapeutic use)
• Drug Therapy, Combination
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Ocular Hypotension (chemically induced)
• Organophosphonates
• Organophosphorus Compounds (adverse effects, therapeutic use)
• Probenecid (therapeutic use)
• Uveitis, Anterior (chemically induced)